# Crinetics

Type: Company (CRNX)

Source: GetYourBrief — https://getyourbrief.com/entity/crinetics
Canonical HTML page: https://getyourbrief.com/entity/crinetics

## Timeline

- **2026-02-26**: EU Regulatory Milestone — Crinetics receives positive CHMP opinion for Palsonify in the European Union.
- **2026-01-15**: Crinetics Capital Raise — Public offering brings Crinetics' total liquidity to approximately $1.4B.
- **2025-12-31**: NVIDIA Reference Status — Aeva 4D LiDAR selected as reference sensor for NVIDIA DRIVE Hyperion.
- **2025-10-01**: Palsonify Launch — Crinetics initiates U.S. commercial launch of Palsonify for acromegaly.

## Recent coverage (3 stories, network-wide)

### Tech Scale-Ups Signal Resilience: Crinetics and Aeva Lead Q4 Growth Surge
2026-02-27 02:09:50 · Sector: startups · Sentiment: Positive · Impact: 7/10 · Sources: 11

A wave of Q4 2025 earnings reports highlights a pivotal shift for growth-stage technology and biotech firms as they transition from R&D to commercial scaling. Crinetics and Aeva Technologies emerged as standout performers, securing massive cash reserves and tier-one partnerships that validate their long-term market positions.
Full story: https://getstartupbrief.com/story/tech-scale-ups-crinetics-aeva-q4-earnings

### Manufacturing Scale-Up and Inventory Volatility Shape Q4 Logistics Outlook
2026-02-27 02:06:59 · Sector: supply · Sentiment: Positive · Impact: 7/10 · Sources: 11

The fourth quarter of 2025 highlighted a critical divide in the industrial supply chain, with advanced materials and sensor manufacturers successfully scaling production while retail and IoT sectors faced significant margin pressure from tariffs and inventory imbalances. Strategic shifts toward diversified procurement and high-value technology partnerships are now defining the competitive landscape for 2026.
Full story: https://getsupplybrief.com/story/q4-2025-manufacturing-logistics-intelligence-brief

### Q4 2025 Earnings: Precision Diagnostics and Endocrine Innovation Drive Growth
2026-02-27 01:33:26 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 3

The Q4 2025 earnings reports from Crinetics, MDxHealth, and Baldwin highlight a pivotal shift toward precision diagnostics and specialized endocrine therapies. These results underscore a robust recovery in diagnostic volumes and a maturing pipeline for rare disease treatments entering commercialization phases.
Full story: https://gethealthbrief.com/story/q4-2025-healthcare-earnings-crinetics-mdxhealth-baldwin

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.